|
Advanced Cancer Patients Treated with GC10-100.
Preliminary Research Period 1993 - 2002.
John Grinstein Ph.D..
INTRODUCTION
Our research studies on cancer were developed in parallel with our studies on Parkinson’s disease and Shy Drager Syndrome.
The responses to a treatment of Parkinson’s disease patients can be easily evaluated, through external observations relating to the ability of a patient to perform movements.
Clinically, these responses are assessed and evaluated, in accordance with conventional PD disability scales and standards.
Our results on Parkinson’s disease contributed to our cancer research studies by revealing that, a dietary intervention, designed specifically to compensate for a biochemical deficiency, could become a very effective therapeutic tool. Sometimes, this type of intervention can become even more effective than an intervention utilizing an isolated chemical or drug.
The application of an intensive dietary intervention never causes serious adverse reactions, as usually occurs when giving high dosages of an isolated chemical.
Our use of dietary interventions in the treatment of cancer can be divided into three different periods:
1. –1993 to 1995
2. - 1996 to 2000
3. - 2001 to 2002
PERIOD 1993 – 1995
During these years, we were dedicated mainly to providing dietary advice, based on the findings of a number of epidemiological studies showing the following:
a) Populations with high consumption of fruit and vegetables have a lower incidence of cancer.
b) Consumption or deficiency in the use of these vegetables is related to serum levels of various molecules, with anti-tumour properties, which originate in fruit and vegetables.
We were part of a non profit institution that donated vegetable extracts, food processors and supplies of organic fruit and vegetables to patients suffering from advanced cancer, in hospices and clinics.
Conclusions from this Period:
A.- Patients using a cancer dietary intervention for 60 days or more, which had to be followed by surgical removal of the tumour, reported to us, on various occasions, that the visual impression from the surgeon and the histological report about the excised tumour, revealed a non proliferative mass of differentiated cells, most of them dead cells. The tissues showed a dry and yellowish appearance. These observations sometimes surprised the surgeons, who expected to see and excise a more active and larger tumour mass.
B.– The response to a dietary intervention, in cancer patients suffering from advanced brain tumours, was usually more rapid than those observed in patients suffering from other forms of cancer. Patients, nurses and carers reported to us that they observed clear improvements, sometimes just one week after starting the treatment. We assumed that these immediate responses were due to the easier penetrability, through the blood barrier, of some anti-tumour molecules, extracted by us from fruits and vegetables.
As an example of this type of result, we enclose a video recording from 1992, of Mr. J. Morley from Newcastle on Tyne. His wife suffered from a very advanced brain tumour. Our extracts had to be administered through a syringe inside her mouth because, following surgery, the patient was unable to take food. The remarkable improvements observed in this patient, encouraged our early research efforts on brain cancer.
PERIOD 1996 - 2000
During this period, our research was mainly concerned with developing analytical chemistry methods to analyze serum and intracellular concentrations of a number of substances, of natural origin, which are known to have either a chemopreventive or a Chemotherapeutic effect.
During this period, we also made substantial progress in the development of food biochemistry methods to characterize, extract and isolate, more than 100 substances and molecular complexes, found in fruit and vegetables, known to have anti-tumour properties.
We continued to suggest dietary intervention programmes, give nutritional advice, and supply medicinal extracts, from selected organic fruit and vegetables, to hospitals, clinics and institutions, to help advanced cancer patients.
During this period, our studies on cancer were carried out with the participation of doctors, hospitals and clinics in various parts of the world
1.- Liver Cancer.
Patient: Joyce Wait. DOB 19/08/1942.
Surrey, England.
Referral: Yr. 1997. The Cancer Prevention Foundation UK.
Radiologist: Dr N Digges.
BUPA Gatwick Park Hospital.
At the time of referral, the last ultrasound abdomen-liver scan had shown a number of malignant focuses, spreading throughout all aspects of the liver. At this stage, doctors believed it was impracticable to offer any further chemotherapy or radiotherapy treatments.
Palliative treatment at home was the only viable offer. However, the patient decided instead, to follow our dietary intervention programme. Our recommendations were based on the results of analytical chemistry studies, done by ourselves on the patient’s serum samples and on the ultra sound scans available.
The patient used three teaspoonfuls a day of the GC17 extract, for 30 days continuously. In addition, the patient strictly followed a dietary intervention programme, with selected organic foodstuffs, delivered twice a week, directly to her home, as part of our charitable programme.
An ultrasound scan was performed on the 2nd of May 1997 at the initiation of the treatment and a second one was performed on the 30th of May 1997. The scans were performed by Dr N Digges, Consultant Radiologist at BUPA Gatwick Park Hospital, UK.
During this 29 day period, we received weekly reports from the health care group which had referred this patient to us.
Their reports indicated that, since day 7 of treatment, the patient had shown increased appetite and was in good shape. Reports from day 15 onwards, stated that the patient was, for the first time in months, gaining weight and that she was now able to go out daily to visit family and friends, and that she was interested in going to places like the cinema and shopping.
A comparative study between both ultra sound scans revealed that, after 30 days of treatment with GC17, for the first time in her liver cancer clinical history, the various malignant focuses, located in the liver, were not showing any further growth or spreading within the liver.
Moreover, the second ultra sound study from 30th of May, revealed a reduction in the size of the main lesion and also a reduction in the size and in the number of metastases. A copy of both ultra sound films is enclosed with this report.
2. - Ovarian Carcinoma.
Patient: Veronica Jones. DOB: 20/04/1940.
Nutley, East Sussex. UK.
Referral: Yr. 1997. Cancer Prevention Foundation UK.
Radiologist: Dr A Hawrych.
BUPA Gatwick Park Hospital.
At the time of referral, the CT scan done on the 25th of March 1997, had shown an ovarian carcinoma consisting of a 16 cm diameter, partly solid, partly cystic mass, located in the pelvic area. The doctors suggested that a hysterectomy could be of some benefit but also pointed out the danger involved. The patient decided to reject this option and requested a referral to be included in our nutritional research programmes
In April 1997, due to the gravity of her condition, we assigned a special nursing assisting team that, over a 30 day period, visited her four times a day, to assist her and to assure full compliance with the dietary intervention programme.
Four weeks later, on the 22nd of April 1997, a second scan was taken by Dr A Hawrych, at BUPA Gatwick Hospital. This scan showed that the diameter of the pelvic tumour mass had reduced in size from 16 cm to 12 cm.
The dietary intervention used by this patient had been quite intensive.
At that stage, in 1997, our research had just begun the manufacturing and preparation of medicinal extracts and food molecular concentrates. Therefore, without most of the extracts available for use today, at that time, a high volume of foodstuff products needed to be taken in order to obtain a response.
This intense effort tired the patient and we had to decrease the strength of the treatment on the 5th of May, in order not to cause a complete rejection by the patient.
The reduction in tumour size, by 25% approximately, was quite impressive, given that the patient never had chemotherapy or radiotherapy before.
The continuation of the initial, very intensive protocol, was almost impracticable, due to the large amount of food and extracts needed.
The positive response obtained with this patient, and the impracticability of a purely food intervention, motivated us in our efforts in developing methods to reduce the volumes of food required, turning them into small volume extracts and concentrates, prepared in such a way, that the anti-tumour effectiveness could be maintained.
During the next two months of treatment, the patient continued with a less intensive dietary intervention. This maintained a steady condition. A third scan, done on the 9th of June, showed no further change or increase in size. The radiologist’s report stated that, the pelvic mass had remained essentially unchanged, since the previous scan done on the 22nd of April.
We concluded from these results that, with a very intensive intervention, the size of a large tumour mass can be reduced by almost 25%, in less than 30 days, and that only with a very intensive dietary intervention, can a significant reduction in the size of a tumour be achieved. By using just a standard or non intensive intervention, the cancer process can only be maintained at a steady level, that is, with no further tumour growth but also no reduction in its size.
We must underline the fact that this patient did not take any other medicine during the dietary intervention. The tumour was first diagnosed when it already had a 16 cm diameter and there was no clinical option other than surgery. The patient had never been previously treated with chemotherapy or radiotherapy. This fact invalidates any suggestion that a delayed response to a previous intervention, could have acted in a synergistic or adjuvant way, to produce this important result.
During this same period, another 10 patients with advanced cancer were included in our dietary intervention programmes in the UK.
These patients, for various reasons, could not keep up with our requests for 30 day interval scans, needed by us to have a practical assessment of the effectiveness of the treatment.
However, we did not reject any of those requests for help and we provided all the facilities and donated all the products needed to help these patients.
The main observations concerning this group of patients were as follows:
A) A rapid increase in appetite. This feature appeared to be in stark contrast with the characteristic weight loss found in most patients with advanced cancer.
B) An immediate decrease in the intensity of pain. As a consequence, a decrease in the need for barbiturates and pain killers followed. This contributed to a decrease in the intensity of swollen limbs and tissues.
C) Renewed interest in performing daily activities.
3.- Lung Cancer. Renal Cell Carcinoma.
Mark Roberts – DOB 20.8.56.
Holly Drive, Littlehampton,
West Sussex. BN17 6LB. UK.
Referral: Yr. 1997 Cancer Prevention Foundation UK.
He started with our treatment on the 27th of June 1997.
A dietary intervention programme was designed, in accordance with the serum samples and with the medical history, as stated in a report from The Royal Marsden NHS Trust, which was provided to us by Mr Mark Roberts.
The patient reported to us that, after four weeks using GC20, in conjunction with our dietary intervention, he could clearly observe a significant reduction in the size of all skin metastasized lesions. This is something he and his wife were easily able to monitor. He confirmed this to us in a video tape, filmed by his wife, showing each one of the skin lesions referred to us on his written report.
He also reported to us that, his breathing capacity had increased markedly and that he felt less pain with no coughing problems.
4.- Liver Cancer. Previously Ovarian Cancer.
Gillian Webb. DOB 20.6.1945.
31 Maybrook Drive,
Sawtash, Cornwall. PL12 4PX.
Referral: Yr. 1996. Cancer Prevention Foundation UK.
This patient was referred to us by a nursing home executive, who was aware of our nutritional research project on cancer.
In 1996, we had not yet developed large scale GC production and the only therapy we could offer, consisted mainly of dietary intervention programmes.
The patient had her first ultra sound scan taken on the 9th of August 1996. She followed the dietary programme for three consecutive weeks, before she expressed to us that, taking the GC extract was too hard for her. The first line of GC extracts, we were able to produce in 1996, did not have a pleasant taste at all.
At that stage in our research, Mr A.W. Smith, a Parkinson’s disease sufferer, who had benefitted significantly from our dietary programme and extracts, became an active sponsor in the advancement of our research on cancer.
Thanks to his efforts and to those of other good hearted people, at the beginning of 1997, with new methods of laboratory production, we were able to manufacture a much more effective line of GC products, with a more palatable and acceptable taste.
The following are the names of three other advanced cancer patients who used our GC10-100 extracts during 1997.
These patients reported to us the benefits they believed they had obtained. However, they did not manage to provide us with the appropriate scans and clinical reports to evaluate and validate their responses.
Maggie Ridell
Shamin Jannohemed
Alistair Hall
5.- Brain Tumour.
Shirley Heaps. DOB 18/04/42.
Mc Allen, Texas, USA.
Referral: Yr. 1997 Dr. Olivares, Texas.
This patient presented a CT scan report to us, indicating a soft tissue mass in the right skull base which measured 3 x 3.5 cm. This represented a recurrent tumour, involving the right side of the posterior nasopharyinx, with erosion of the skull base.
The patient suffered a blockade of the esophagus, so it was not possible to suggest any dietary intervention involving food ingestion
The patient sent us in the UK, various serum samples for analysis. A GC35 batch was produced and sent to the patient.
The GC35 was administered topically. A one inch band of the extract was spread daily over her back throughout the spinal cord and was left there for an hour.
GC35 is a highly lipid soluble product, therefore it easily penetrates through the skin and is absorbed into the circulatory system.
The GC35, as with most GC extracts, penetrates easily through the blood brain barrier.
The patient was able herself, to corroborate the absorption of GC35. She could feel the taste of the extract just a few minutes after application. Her husband also reported to us that the extract appeared visible in the patient’s stools.
This very advanced cancer patient was under hospice home care. Three times a day, visiting nurses helped her with all her needs.
The nurses in charge, soon became very impressed with the rapid changes they observed. The patient started to be active at home and became able to perform daily activities like, managing her washing machine, vacuum cleaner and she personally washed her dishes. During this period, she felt active and stopped experiencing pain.
Her husband recorded to us a testimonial, (CD enclosed here) informing in detail about his wife’s responses.
The above experience suggested to us that topical applications with GC35, could be an effective route to allow absorption in advanced cancer patients who are unable to swallow or digest food properly.
6.- Glioblastoma Multiforme.
Sunni W O’Neal. Age 49.
6612 Cantaloupe Ave.,
Van Nuys, CA 91405. USA.
Referral: Yr. 1997. UCLA. Dr. T. Cloughesy.
At the time of referral in October 1997, the patient had just completed treatment with intra-arterial carboplatinum and high dose tamoxifen. An MRI, taken a few weeks after treatment, indicated tumour recurrence. The patient had exhausted all viable treatment. On the 1st of November, following our analysis of the patient's blood serum, the patient started on the extract GC20 (Gimmel), one tsp., four times a day.
Previous MRI scans had shown that the tumour had an average growth of approx. 50%. in two months.
The MRI, taken at UCLA at the end of November, following one month of treatment with GC20, showed only a 5% increase in tumour size.
In 1997, GC20 had just been developed and could only be produced after a complicated laboratory process. It could not yet be produced in enough quantity to assure a continuous supply.
The patient’s faith in our protocols and the impressive cessation of tumour growth, observed in a Glioblastoma Stage IV, encouraged us to plan a proposal for undertaking a clinical trial on the use of GC10-100, for the treatment of glioblastoma.
7.- Neuroblastoma Stage 4S.
James Schneeberger. Age 5.
3244 Citron Drive,
Maples FL 34120. USA.
Referral. Yr. 2000. Biochemistry Research Institute UK.
Neuroblastoma is the most common malignancy in infants, accounting for half of all infantile cancer. At onset, two-thirds of patients with neuroblastoma are under 5 years of age. Our research on Cancer Cell Biology was initiated in 1989. Results with the Neuroblastoma GOTO Cell Line, then showed us the strong inhibitory effects of GC10-100 on cancer cell proliferation.
When we tested the effect of GC10-100 on the Glioblastoma Cell Line A172, we noticed that GC10-100 were 5 times more effective in inhibiting proliferation of neuroblastoma than glioblastoma cell lines.
There is usually great skepticism regarding any results on cancer based on research therapies derived from natural sources. This skepticism is prevalent in young couples with modern views on life. Here, neuroblastoma is causing the greatest and most devastating effect.
Mrs. Debbie Schneeberger, the mother of 5 year old James, suffering from Neuroblastoma Stage 4S, decided to ask for samples of our GC10-100, despite the skepticism of family and friends
On the 4th of January 2000, we sent 4 samples of GC2 (FedEx Bill No. 444479352088) that she used straight away and found that her son had an immediate and very positive response.
On the 14 of January, we received the patient’s serum samples. Our analysis of these samples, indicated that GC15 would be the most effective product. The patient took GC15 for 3 consecutive weeks.
During this period, we received various reports indicating a significant improvement in James’s condition.
While still on treatment with GC15, Mrs. Schneeberger received an offer for James to participate in a clinical trial on a new drug. She traveled to Florida and started James on the trial. As a result of this, the use of GC15 had to be discontinued.
The trial could not provide a real help to James who was taken back home after the trial, in a state of coma.
It was a sad experience for me to hear about, as the mother told me personally of her regrets over her previous decision to interrupt the treatment with GC15.
We concluded however, that the rapid improvement shown in this very young patient, had reinforced the previous results from our neuroblastoma cell biology research. GC10-100 could become very effective tools, to help in the treatment of children with advanced neuroblastoma.
8.- Glioblastoma Brain Tumour.
Julie Liccardi, Age 37.
1645 Route 22 West,
Watchung, NJ 07060. USA.
Referral: Year 2000, Paracelsus Clinic, Switzerland.
This patient used GC20, taking 4 tsp a day, in conjunction with treatment that was prescribed for her at the Paracelsus Clinic, Switzerland. A 2 ml sample of separated serum was sent to us from the clinic in February 2000. Soon after, the patient started using GC20, in doses of 5 tsp. a day. An MRI, taken 30 days after starting the treatment with GC20, showed that there had been no tumour growth during this 30 day period. We could not continue to provide the treatment to this patient, because some of the interventions prescribed by the clinic, although promising, were not compatible with the use of our extracts. These included, high dosages of ascorbic acid and hypothermic therapy
9.- Metastatic Breast Cancer.
Erin Kramp, DOB 5.02.62.
906 West Randal Mill Road,
Arlington, Texas. USA.
Referral: Yr. 1997. Dr G. Blumenschein.
Arlington Cancer Center.
The medical report, included with the referral, indicated metastatic breast cancer and lymphangitis had spread to the lungs. Despite treatment with numerous types of chemotherapy, a recent CT scan of the chest revealed evidence of disease progression. The patient had exhausted all viable treatments.
This seriously ill young patient was living by herself. She could not arrange for the serum samples that we had requested to be sent to us. However, we provided her with a basic GC10 extract until she could make arrangements to send the serum samples to us.
This did not materialize and we continued sending her GC10 at her request. She told us that the extract GC10 was giving her some relief from her main symptoms. She used GC10 for a period of approx. 6 months. Later on, she moved to a new address and we lost contact with her.
10.- Medulloblastoma.
Ayman Khayyat, DOB 15.1.98.
Jedda, Kingdom of Saudi Arabia.
Referral Yr. 1998, King Fahad Hospital, Jedda.
The above patient was treated with our GC line of extracts as part of a collaborative effort between The Prince Majed Centre of The King Fahad Hospital in Jedda and our Biochemistry Research Institute in the UK.
The hospital in Jedda organized a team, consisting of a neurooncologist, a pharmacist, a gastroenterologist and a Natural Medicine Consultant, to evaluate and select the patients participating in our collaborative study.
We highlight here, the results obtained with one of the patients, 3 month old A. Khayyat. This patient was treated by Dr Nadia Mandura in Jedda.
At the time of referral, the histopathological report described a 3.5 cm. medulloblastoma of neuroblastic type. The tumour was partially excised and the patient started using the extract GC10, three weeks after surgery. There was very little hope that this patient would be able to survive for more than a few weeks after surgery. However, the patient responded very well to the first 3 weeks of therapy with GC10.
Dr Mandura increased the dosage gradually, from one tsp. a day, to 3 tsp. a day. The extract was dissolved in the milk or juice in his bottle.
Dr Mandura’s reports indicated that a total of 3 tsp. a day were easily taken by this now 4 month old infant.
Our adult cancer patients were using an average of 4 to 5 tsp a day of GC10-100. We assumed then that 3 tsp. a day, on a 4 month old child, was a very intensive dosage.
The reports from Dr Mandura indicated to us, the excellent absorption of the GC10 she was able to observe in her patient. There were no side effects or digestive complications whatsoever. This encouraged us to increase the maximum daily dosages of GC10-100 in adult cancer patients to 8 tsp. a day.
The GC10 extract was used by this patient for a period of 6 months. After this period, the patient appeared to be completely free of any form of recurrence or any further complications.
To comply with a continuous need to supply this patient and that of many others in this study in Jedda, the public relations department of Saudi Airlines, at Heathrow Airport, London, provided us with crucial assistance. All our fresh or frozen extracts arrived at the hospital in Jedda in less than 8 hours after it was taken to Heathrow Airport from our biochemistry research laboratory in Uxbridge, UK.
From this collaboration between the doctors at the King Fahad Hospital and our team, we would like to highlight the following conclusions:
The medical contribution coming from the doctors in Jedda, was a determinant factor in obtaining the successful result for the patient above and for other cancer patients treated in Jedda with our extracts.
A biochemist/oncologist collaboration was complementary in reaching better results.
We believe that this form of cooperation should be the essential framework for all future studies or clinical trials.
YEAR 2001-2003
11.- Adenocarcinoma of the Lung.
Janet Turnbull, DOB 20.09.48.
72 Southwold Road.
London E5. UK.
The first X-ray on the 28th of September 2001, showed a large opaque mass in the right lung. Bronchoscopy, Biopsy and CT scans of the chest and abdomen, undertaken on the 5th of October 2001, revealed an inoperable Grade 4 Adenocarcinoma.
A second chest X-ray, taken on the 30th of October, revealed a collapse of the right upper lobe, due to further involvement of the right upper lobe bronchus. Following these events, her oncologist at Barts Hospital, London, Dr Rudd, and a lung specialist she visited privately, Dr Frances Bowen, at Hammersmith Hospital, London, could only offer her palliative forms of treatment.
The patient, a practicing nurse, who had been, for many years, in contact with our research programmes, decided to take part in our studies and she rejected the palliative alternatives offered.
The patient provided us with the necessary serum samples, and a dietary intervention was suggested. On the 1st of November, she started taking the GC17 extract, specially designed for her case.
She started with 1 tsp. a day and increased it rapidly to 7 tsp. a day after ten days.
CT scans were taken on the 5th of October 2001, 5th of December 2001 and 10th of January 2002. Chest X-rays were taken at intervals of 20 days approx.
The initial X-ray, on 28 September 2001, showed a tumour mass of approx. 4 to 5 cm. in diameter. The chest X-rays taken on 30th of October, showed a tumour mass with presumed satellite metastases, had grown up to 8 cms. in diameter.
A CT scan, taken on the 5th of December 2001, one month and five days after intensive use of GC17 extracts, showed that the rapidly growing 8 cm diameter tumour had now ceased its growth. Its size had reduced from 8 cm to 7 cm in diameter. This however still remained a very large lesion.
We must underline the fact that, just a few days before starting the use of GC17, the upper right lobe of the left lung had collapsed, due to the increase in tumour size. As a result of this collapse, an obstruction to the airways was expected to occur, at any moment, with tragic consequences.
However, during the next 4 months, in which the patient was treated with GC17, this predicted obstruction of the airways never occurred. The opposite actually took place. In chest
X-rays, taken on the 22nd of February, the degree of collapse of the right upper lobe, showed a substantial decrease.
During her treatment with GC17, we observed that pleural effusions tended to increase in volume when the patient used analgesics. These types of medicine relieve pain by altering perception of nociceptive stimuli, without producing anesthesia or loss of consciousness. At the cellular level, they act by blocking cell membranes. Analgesics and barbiturates are lipid soluble molecules that remain within the lipid bilayer membrane of cells, interfering with the transmission of signals between cells.
Cell membrane biochemical interactions are then blocked and pain signals are obstructed.
Because of the blocking of the transport of substances in the cell membrane, cell fluids are not properly transported and drained outside cells and tissues. As a result, interstitial fluid accumulates in larger amounts, especially in areas with intensive macrophage activity, like the one surrounding a tumour.
Pleural effusion consists of an accumulation of fluid in areas of the pleura adjacent to the tumour. This excess of fluid needs to be drained, periodically, in patients suffering from adenocarcinoma of the lung.
The first drainage of a pleural effusion, done to this patient, took place in December 2001. A 1 litre yellowish liquid was drained at The Hommerton Hospital, London. Microscopic cell examination, at the Pathology Department, showed that the pleural fluid drained, included malignant mesothelial cells and lymphocytes.
To assess whether our extracts were producing an internal change in the activity of the tumour, we decided that, when the next pleural effusion drainage would be required, samples of the fluid should be sent to us, together with copies of the Hospital Cell Pathology Report.
On the 19th of January 2002, we asked Dr Brian O’Connor from the Department of Respiratory Medicine at King’s College Hospital, London, to arrange a private consultation at the Cromwell Hospital, London, for Janet Turnbull, to decide if a pleural effusion drainage was needed. This proved to be the case.
We asked Dr O’Connor to arrange that samples of the fluid be sent to our Biochemistry Laboratory together with a copy of the hospital’s pathology cell report on the pleural fluid.
A specialist, that we had consulted previously for a second opinion, agreed that, due to the severity of the disease, the pathology report would indicate a similar outcome to the previous one. That suggested that malignant cells, would be present in the fluid, mainly because they are drained from areas that are in close contact with the tumour
On the 19th of January 2002, Dr O’Connor performed the drainage of the pleural effusion at Cromwell Hospital, and, on the 21st of January, a report on the specimen, sent by Dr O’Connor was received back from P.D Lewis, M.D., D.Sc., F.R,C.P., F.R.C. Path. of London Pathology Associates.
This report revealed that “ The specimen contains benign mesothelial cells and lymphocytes. No malignant cells seen.”
These results, corroborated our own laboratory test, and, in addition, showed that, in the drained pleural fluid, there was a very high concentration of GC17.
We concluded that, GC17 had exerted its therapeutic effect in a lung adenocarcinoma, in a similar way, as it had before in other forms of cancer. This was by inducing malignant cells to differentiate into benign, non proliferative, cells.
For this reason, the tumour mass did not show any growth during GC17 treatment, but instead, showed a gradual and slow reduction in size, which corresponds to a malignant focus, turning into a benign and non proliferative mass, in which cells have been induced to differentiate, mature and die.
GC-17 induced a reversal of the malignant process, and this is why the tumour did not show any significant growth over 5 months. The collapse of the upper right lobe was reduced, instead of collapsing further and closing the airways, as had been expected.
We hope this report will help, in the understanding of the biochemical paths provoked by GC17, in relation to its activity in inducing differentiation of malignant cells.
Apoptosis really means, a “programmed” cell death, but is often confused with an “induction” of cell death by a cytotoxic agent. Induction of cell death, is a rapid process in which cancer cells are killed by radiation or by interfering with its DNA replication. The results can be observed immediately after treatment. By inducing a “programmed cell death,” malignant cells have first to differentiate, in other words, they have to reverse to a benign stage, then mature and die. Therefore, the reduction in size is not as rapid as in a cytotoxic or radiation approach. GC17 allows the differentiation of all malignant focuses and metastases in the body, with no side effects and without the killing of normal cells.
|
